# psoriasis - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 47684
- Completion tokens: 16103
- Reasoning tokens: 0
- Total tokens: 63787
- API requests reported: 3
- Elapsed seconds: 135.582
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: OpenAI

---
# Overall interpretation

The profile is a strong lesional-psoriasis state signature rather than a subtle transcriptional shift: **90 of 100 genes are upregulated and 10 are downregulated**, and all 100 meet **FDR ≤ 0.01**. The dominant pattern combines:

- activation of the **IL-36/IL-17-associated inflammatory epithelial axis**;
- marked induction of **antimicrobial peptides and innate host-defense genes**;
- remodeling of keratinocyte differentiation and the **cornified envelope**;
- evidence of **myeloid/neutrophil-associated inflammation**; and
- increased epithelial stress, proliferation, and tissue remodeling.

Representative effect sizes are very large: **IL36A, log2FC=11.373575; DEFB4A, log2FC=11.182922; DEFB4B, log2FC=11.030811; S100A7A, log2FC=9.832667; PI3, log2FC=9.240380; SERPINB4, log2FC=9.118136**. The coordinated direction across multiple related genes makes the overall biological interpretation coherent.

These results provide strong **within-cohort differential-expression evidence**. However, **external statistical validation was not performed**: the evidence pack contains no independent-cohort effect sizes, P values, or FDR values. Pathway, network, tissue, and literature records therefore support biological plausibility but do not constitute replication.

## Core biological programs

### 1. IL-36/IL-17-associated inflammatory epithelial signaling

**Direction:** Upregulated in lesional skin.

**Major supporting genes:**  
**IL36A** (log2FC=11.373575), **IL36G** (5.6840917), **IL19** (7.5795008), **IL20** (5.6674194), **IL26** (4.3612172), **IL36RN** (3.0051655), **IRAK2** (2.0828134), **CXCR2** (2.7005582), and **CD274** (3.4395134).

**Relevant standardized pathways:**

- Reactome: **Interleukin-36 pathway**
- Reactome: **Interleukin-20 family signaling**
- KEGG: **IL-17 signaling pathway**
- KEGG: **Cytokine-cytokine receptor interaction**
- GO: **inflammatory response** and **response to lipopolysaccharide**

**Interpretation:**  
The simultaneous induction of IL36A and IL36G, several IL-20-family cytokines, IRAK2, and CXCR2 is consistent with an activated inflammatory circuit involving epidermal cells and infiltrating immune cells. **IL36RN**, which encodes an IL-36 receptor antagonist, is also increased. This opposing change is biologically compatible with a local feedback response rather than evidence that IL-36 signaling is inhibited overall. The external annotation specifically supports IL36RN binding to the IL-36 receptor complex and antagonizing IL-36 signaling; STRING reports an interaction between **IL36RN and IL1RL2** with confidence 0.999 and between **IL36RN and IL36G** with confidence 0.864. These are database-supported relationships, not interactions measured in this cohort.

**Evidence strength:** Strong direct transcriptomic evidence for activation of an inflammatory epithelial program; pathway and protein-function evidence are concordant.

**Limitations:** The data are bulk lesional skin, so the relative contributions of keratinocytes, T cells, dendritic cells, neutrophils, and other cells cannot be assigned. The supplied pathway records were retrieved before synthesis and were not recomputed here; formal enrichment statistics are not available.

---

### 2. Antimicrobial peptide and innate barrier defense

**Direction:** Strongly upregulated.

**Major supporting genes:**  
**DEFB4A** (11.182922), **DEFB4B** (11.030811), **DEFB103A** (5.7579506), **DEFB103B** (5.7513848), **PI3** (9.2403801), **S100A7** (7.0947825), **S100A7A** (9.8326673), **S100A8** (7.7293672), **S100A12** (8.3288322), **TCN1** (8.0353765), **GPR15LG** (5.5162775), and **PLA2G4D/PLA2G4E**.

**Relevant standardized pathways:**

- GO: **antimicrobial humoral response**
- KEGG: **IL-17 signaling pathway**
- KEGG: **Staphylococcus aureus infection**
- GO: **response to lipopolysaccharide**

**Interpretation:**  
The coordinated elevation of beta-defensins, PI3, S100A-family genes, TCN1, and lipid-modifying enzymes indicates enhanced epidermal innate defense and inflammatory antimicrobial activity. The strong DEFB4A/DEFB4B signal is especially consistent with an IL-17-responsive epithelial state. The “Staphylococcus aureus infection” pathway should be interpreted as a host-defense annotation, not as evidence that the samples were infected with *S. aureus*.

**Evidence strength:** Strong direct evidence from multiple functionally related genes, supported by GO and KEGG annotations and by disease-relevant literature context. The supplied literature search included psoriasis biomarker work involving integrated co-expression and LASSO analysis (PMID: **40560938**), but this does not provide independent statistical replication of the present gene-level results.

**Limitations:** Antimicrobial transcripts may reflect both keratinocyte activation and altered microbial exposure or colonization. The current data do not establish pathogen presence, antimicrobial activity, or causality.

---

### 3. Keratinocyte differentiation and cornified-envelope remodeling

**Direction:** Strongly upregulated, with selected barrier-associated genes downregulated.

**Major supporting genes:**  
**SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G**, **SPRR3**, **LCE3A**, **LCE3D**, **KRT6A**, **SERPINB3**, **SERPINB4**, **SERPINB11**, **GJB2**, **GJB6**, **TMPRSS11D**, **KLK13**, **PRSS27**, and **RHCG**.

**Relevant standardized pathways:**

- Reactome: **Formation of the cornified envelope** (R-HSA-6809371)
- GO: **epidermis development**
- GO: **epithelial differentiation**
- GO: **cell junction** and barrier-related processes, where applicable

**Interpretation:**  
The coordinated induction of small proline-rich proteins, late cornified-envelope genes, keratins, serine proteases, and epithelial junction genes indicates substantial keratinocyte differentiation remodeling. This is compatible with the altered epidermal architecture and hyperkeratotic phenotype of psoriatic lesions. The Reactome record links 12 selected genes, including **KLK13, KRT6A, LCE3A, LCE3D, and PI3**, to cornified-envelope formation.

The accompanying downregulated genes—such as **WAKMAR1** (log2FC=-5.6275936), **LOC107984452** (-6.2487486), **SAPCD1** (-2.9369913), and **UGT3A2** (-4.5907749)—show that the response is not a uniform increase in all epidermal genes. This may reflect a shift toward a disease-associated keratinocyte state rather than generalized epithelial activation.

**Evidence strength:** Strong direct evidence for coordinated epithelial remodeling; pathway evidence is supportive.

**Limitations:** Bulk-tissue expression cannot distinguish true transcriptional reprogramming within keratinocytes from increased abundance of particular keratinocyte subpopulations. Formal cell-state or single-cell analysis is needed.

---

### 4. Myeloid/neutrophil-associated inflammatory component

**Direction:** Upregulated.

**Major supporting genes:**  
**S100A8** (7.7293672), **S100A12** (8.3288322), **TCN1** (8.0353765), **PLBD1** (2.0765475), **CXCR2** (2.7005582), **GPR15LG** (5.5162775), **TRIM15** (4.5439236), **ACP7** (3.7663477), and **S100A7** (7.0947825).

**Relevant standardized pathways:**

- GO: **response to lipopolysaccharide**
- GO: **innate immune response**
- KEGG: **cytokine-cytokine receptor interaction**
- KEGG: **IL-17 signaling pathway**

**Interpretation:**  
The S100A8/S100A12 pair, TCN1, PLBD1, and CXCR2 is compatible with accumulation or activation of neutrophil- and myeloid-associated cells in lesional skin. This complements the epithelial inflammatory program: epithelial cytokines and chemokines may help sustain recruitment of inflammatory cells, while myeloid-derived mediators may reinforce epidermal activation.

**Evidence strength:** Strong expression evidence for a myeloid-associated component; pathway annotations support innate inflammatory interpretation.

**Limitations:** This is the program most vulnerable to a cell-composition explanation. The data do not demonstrate that these genes were induced within resident keratinocytes or prove a specific neutrophil recruitment mechanism.

---

### 5. Epithelial stress, proliferation, and tissue remodeling

**Direction:** Upregulated, with selected changes suggesting altered growth-factor signaling.

**Major supporting genes:**  
**KRT6A** (4.3025579), **RRM2** (2.7179913), **CCNE1** (2.5573733), **CDK5R1** (2.3503019), **WNT5A** (2.5264849), **HPSE** (2.9241399), **HABP2** (4.191812), **AKR1B10** (6.2653691), **AKR1B15** (5.2310671), and **FABP5** (3.6445647). **BTC** is downregulated (log2FC=-4.2989343).

**Relevant standardized pathways:**  
Relevant annotations include epithelial development, extracellular-region functions, WNT-related signaling, and tissue-remodeling processes; however, no formal pathway-level P value was supplied for this program.

**Interpretation:**  
KRT6A, RRM2, and CCNE1 are compatible with activated or proliferative keratinocytes, while WNT5A, HPSE, HABP2, and lipid/oxidative metabolism genes suggest changes in tissue remodeling and epithelial stress responses. The opposing direction of **BTC** indicates that growth-factor signaling is not globally increased and should not be reduced to a single “EGFR activation” model.

**Evidence strength:** Moderate direct evidence, because the signal is distributed across several functional categories but is less specific than the IL-36, antimicrobial, and cornified-envelope programs.

**Limitations:** RRM2 and CCNE1 do not by themselves establish increased cell division; cell-cycle assays and histologic proliferation measurements are required. The interpretation may also be influenced by lesion thickness and altered epithelial composition.

## Key genes and interaction modules

The following candidates are prioritized for biological follow-up, not because external records establish their statistical importance, but because they connect strong uploaded effects with interpretable biology.

1. **IL36A–IL36G–IL36RN inflammatory module**  
   **IL36A** and **IL36G** are upregulated, with log2FC values of **11.373575** and **5.6840917**, respectively; **IL36RN** is also upregulated at **3.0051655**. IL36A/G are putative inflammatory agonists and IL36RN is an antagonist. The relationship is a **regulatory/signaling relationship**, not a demonstrated physical interaction in the uploaded data. External records support IL36RN binding to IL1RL2 and functional antagonism of IL-36 signaling. The simultaneous rise of agonist and antagonist transcripts suggests activation with compensatory feedback.

2. **DEFB4A–DEFB4B–DEFB103A/B antimicrobial module**  
   All four genes are strongly upregulated, including **DEFB4A log2FC=11.182922** and **DEFB4B log2FC=11.030811**. They are **pathway co-members** and functionally related antimicrobial effectors. This does not imply direct physical interaction among the defensin proteins.

3. **S100A7–S100A7A–S100A8–S100A12 inflammatory module**  
   These genes are all upregulated, with log2FC values from **7.0947825 to 9.8326673**. Their relationship is best described as **co-expression and pathway/functional co-membership** involving epithelial stress and innate inflammation. Direct physical interaction was not established by the supplied records.

4. **SPRR/LCE cornified-envelope module**  
   The SPRR family and **LCE3A/LCE3D** are broadly upregulated; examples include **SPRR2A log2FC=7.31208**, **SPRR3=7.1797512**, **LCE3A=8.2975962**, and **LCE3D=5.314054**. STRING records connect several SPRR genes and KRT6A, but the precise relationships may include database-assigned functional association or co-occurrence. They should be described as **network association and pathway co-membership**, not automatically as direct physical interactions.

5. **KRT6A–SPRR/LCE epithelial remodeling module**  
   **KRT6A** is upregulated at **4.3025579** and is linked by the supplied Reactome annotation to cornified-envelope formation with several SPRR/LCE genes. This is a **pathway co-membership** relationship, with possible co-expression in lesional keratinocytes.

6. **IL36 receptor-complex relationship: IL36RN–IL1RL2–IL1RAP**  
   Only **IL36RN** is directly measured among the central antagonist components in the selected list, while external records identify IL1RL2 and IL1RAP as receptor-complex partners. The relationship is a **direct ligand/receptor-complex interaction according to external protein-function/database evidence**, but it was not measured experimentally in this study.

7. **S100A7–FABP5–SERPINB3/SERPINB4 network**  
   STRING records associate **S100A7** with **FABP5, S100A12, S100A7A, SERPINB3, and SERPINB4**. These should be treated as **database network associations**, potentially reflecting co-expression, functional association, or literature-derived links; the supplied context does not establish direct physical binding.

8. **CXCR2-associated inflammatory recruitment signal**  
   **CXCR2** is upregulated at **2.7005582**, together with S100A8/A12 and other inflammatory genes. This is an **indirect or putative recruitment relationship** consistent with a neutrophil-associated program, not evidence that CXCR2 caused the observed lesion phenotype.

9. **CD274 immune-regulatory signal**  
   **CD274** is upregulated at **3.4395134**. Its relationship to the inflammatory programs is a **regulatory or contextual association**: increased PD-L1 may reflect local immune activation and feedback. The supplied literature search includes work on anti-CD274 strategies (PMID: **38354028**), but that oncology-focused evidence does not establish psoriasis efficacy.

10. **WNT5A–HPSE–HABP2 remodeling signal**  
    **WNT5A**, **HPSE**, and **HABP2** are upregulated, but their joint interpretation is a **putative tissue-remodeling association**. The current data do not demonstrate a physical complex, direct regulation, or causal remodeling pathway.

## Validation priorities

### 1. Test the IL-36 inflammatory circuit in lesional keratinocytes

**Classification:** Mechanistic hypothesis.  
**Why prioritize:** IL36A is the largest positive cytokine effect in the table, and IL36G, IL19, IL20, IL26, IRAK2, and IL36RN are concordantly increased.  
**Current evidence:** Direct differential expression: **IL36A log2FC=11.373575, FDR=1.6547601e-98**; **IL36G log2FC=5.6840917, FDR=1.4283826e-90**.  
**External evidence:** Reactome and UniProt support an IL-36 signaling system, while STRING supports IL36RN relationships with IL1RL2, IL1RAP, and IL36G. These are contextual and may derive from overlapping curated sources.  
**Next step:** Perform spatial transcriptomics or multiplex immunostaining for IL-36 ligands, IL1RL2, IL1RAP, and IL36RN, followed by primary keratinocyte perturbation with IL-36 agonists or antagonists.  
**Conclusion level:** **Supported hypothesis**, not causal proof.

### 2. Validate an antimicrobial/barrier signature as a lesional biomarker

**Classification:** Biomarker.  
**Why prioritize:** Multiple defensins, PI3, S100A7-family genes, and cornified-envelope genes show very large effects.  
**Current evidence:** **DEFB4A, DEFB4B, PI3, S100A7A, S100A7, and LCE3A** are all strongly upregulated with very low FDR values.  
**External evidence:** GO and KEGG annotations support antimicrobial humoral response, IL-17 signaling, and host-defense biology.  
**Next step:** Test the signature in an independent psoriasis cohort, including lesional, nonlesional, and normal skin, and assess association with clinical severity and treatment response.  
**Conclusion level:** The signature is an **established observation within this dataset** but an **exploratory biomarker** until independently validated.

### 3. Separate keratinocyte reprogramming from immune-cell composition

**Classification:** Confounding or composition check.  
**Why prioritize:** S100A8, S100A12, TCN1, PLBD1, and CXCR2 could reflect increased neutrophil or myeloid-cell abundance rather than transcriptional induction in keratinocytes.  
**Current evidence:** Coordinated upregulation of myeloid-associated genes alongside epithelial inflammatory genes.  
**External evidence:** Tissue-expression and pathway annotations support plausible immune and epithelial roles, but they do not resolve cellular origin.  
**Next step:** Use single-cell RNA-seq, cell deconvolution with validated reference signatures, or spatial profiling; confirm with immunohistochemistry for neutrophils, myeloid cells, and keratinocytes.  
**Conclusion level:** **Supported composition hypothesis** requiring direct testing.

### 4. Test the SPRR/LCE/KRT6A epithelial remodeling network

**Classification:** Interaction / network hypothesis.  
**Why prioritize:** Numerous SPRR and LCE genes, KRT6A, junction genes, and proteases move in the same direction, and Reactome identifies cornified-envelope co-membership.  
**Current evidence:** Strong coordinated expression, including **KRT6A log2FC=4.3025579**, **SPRR2A=7.31208**, and **LCE3A=8.2975962**.  
**External evidence:** Reactome supports formation of the cornified envelope; STRING provides network associations among several SPRR genes and KRT6A. The exact molecular relationship is not established.  
**Next step:** Validate spatial co-localization and protein-level changes, then perturb selected SPRR/LCE or KRT6A nodes in organotypic human skin models.  
**Conclusion level:** **Supported hypothesis** for a coordinated epithelial state; causal network claims remain exploratory.

### 5. Evaluate IL-36 or IL-17-axis intervention only in disease-relevant models

**Classification:** Therapeutic target.  
**Why prioritize:** The transcriptomic profile strongly implicates inflammatory cytokine signaling, making this axis biologically testable.  
**Current evidence:** Upregulation of IL36A/G, IL19, IL20, IL26, DEFB4A/B, and related genes.  
**External evidence:** Pathway and literature records support biological plausibility, but no supplied independent clinical statistic demonstrates that a particular transcript or pathway node predicts therapeutic response. The existence of drugs targeting related pathways is not, by itself, evidence of efficacy for this dataset.  
**Next step:** Test pathway blockade in keratinocyte–immune co-cultures, organotypic skin, and appropriately powered clinical or external transcriptomic datasets with treatment outcomes.  
**Conclusion level:** **Exploratory therapeutic hypothesis**, not an established treatment recommendation.

## Limitations and alternative explanations

1. **Cellular composition:** Lesional skin contains altered proportions of keratinocytes, neutrophils, T cells, dendritic cells, and other immune populations. This is particularly relevant to **S100A8, S100A12, TCN1, PLBD1, and CXCR2**. Single-cell or spatial profiling is the most direct distinction.

2. **Lesion severity and epidermal thickness:** Strong keratin, SPRR, LCE, RRM2, and CCNE1 signals may partly reflect increased or altered keratinocyte abundance and hyperplasia. Histology, Ki-67 staining, and matched nonlesional samples would help separate composition from per-cell regulation.

3. **Treatment and clinical covariates:** Medication exposure, disease duration, lesion site, age, sex, and severity are not provided. These factors can alter inflammatory and barrier programs and should be modeled in replication cohorts.

4. **Batch and platform effects:** Although the statistical results are internally highly significant, technical metadata, sample size, normalization method, and effect-size confidence intervals are not supplied. The unusually large effect sizes and extremely small P values warrant inspection of sample-level distributions, sequencing depth, zero inflation, and possible sample or batch separation.

5. **Association versus causation:** The transcriptome describes the lesional state; it does not show whether IL-36 signaling, defensin induction, keratinocyte remodeling, or myeloid infiltration initiates psoriasis or merely maintains it. The external evidence pack contains extensive annotations, but **external statistical validation was not performed**, and no causal conclusion should be drawn from pathway recurrence, STRING edges, or literature support alone.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=17, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
